Eagle Health Investments LP Takes Position in Soleno Therapeutics, Inc. $SLNO

Eagle Health Investments LP acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 135,100 shares of the company’s stock, valued at approximately $6,255,000. Soleno Therapeutics comprises approximately 1.4% of Eagle Health Investments LP’s holdings, making the stock its 20th largest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Soleno Therapeutics by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock valued at $141,695,000 after acquiring an additional 253,212 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Soleno Therapeutics by 25.7% during the third quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock valued at $174,258,000 after acquiring an additional 527,777 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Soleno Therapeutics by 272.3% during the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock valued at $156,298,000 after acquiring an additional 1,691,057 shares in the last quarter. Invesco Ltd. boosted its position in shares of Soleno Therapeutics by 132.3% during the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock valued at $101,435,000 after buying an additional 854,551 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Soleno Therapeutics by 20.2% during the second quarter. State Street Corp now owns 1,404,983 shares of the company’s stock valued at $117,709,000 after buying an additional 235,784 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

Shares of NASDAQ:SLNO opened at $53.01 on Thursday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of 29.95 and a beta of -2.22. The company has a quick ratio of 5.32, a current ratio of 5.62 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a 12-month low of $29.43 and a 12-month high of $90.32. The business’s 50 day moving average is $45.79 and its 200 day moving average is $45.46.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. Soleno Therapeutics had a return on equity of 22.85% and a net margin of 33.70%.The business had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. On average, sell-side analysts forecast that Soleno Therapeutics, Inc. will post 3.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen cut Soleno Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Oppenheimer cut their target price on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. TD Cowen cut Soleno Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the company from $85.00 to $53.00 in a research report on Tuesday, April 7th. Wells Fargo & Company set a $53.00 target price on Soleno Therapeutics and gave the company an “equal weight” rating in a research report on Friday, April 17th. Finally, Lifesci Capital cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $76.67.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.